人民财讯8月15日电，企查查APP显示，近日，南京诺泰赞生物制药有限公司成立，注册资本2000万 元，经营范围包含：生物基材料技术研发；工业酶制剂研发；生物饲料研发；生物化工产品技术研发 等。企查查股权穿透显示，该公司由ST诺泰(688076)、诺唯赞(688105)等共同持股。 ...

证券代码：688105 证券简称：诺唯赞 公告编号：2025-031 南京诺唯赞生物科技股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 回购方案首次披露日 2025/6/20 回购方案实施期限 2025 年 6 月 19 日~2026 年 6 月 18 日 预计回购金额 500万元~1,000万元 □减少注册资本 √用于员工持股计划或股权激励 回购用途 □用于转换公司可转债 □为维护公司价值及股东权益 累计已回购股数 0股 累计已回购股数占总股本比例 0% 累计已回购金额 0万元 实际回购价格区间 0元/股~0元/股 一、 回购股份的基本情况 南京诺唯赞生物科技股份有限公司（以下简称"公司"）于 2025 年 6 月 19 日 召开第二届董事会第十七次会议，审议通过了《关于以集中竞价交易方式回购公 司股份方案的议案》，同意公司以不低于人民币 500 万元（含）且不超过人民币 民币普通股（A 股）股票，用于实施股权激励或员工持股计划，回购价格不超过 人民 ...

证券日报网讯 8月1日晚间，诺唯赞发布公告称，截至2025年7月31日，公司尚未实施股份回购。 （文章来源：证券日报） ...

证券代码：688105 证券简称：诺唯赞 公告编号：2025-031 南京诺唯赞生物科技股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：688105 证券简称：诺唯赞 公告编号：2025-031 二、回购股份的进展情况 截至 2025 年 7 月 31 日，公司尚未实施股份回购。 三、其他事项 | 回购方案首次披露日 | 2025/6/20 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2025 年 6 6 月 | 月 | 19 | 日~2026 | 年 | 18 日 | | 预计回购金额 | 500万元~1,000万元 | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | | □用于转换公司可转债 | | | | | | | | □为维护公司价值及股东权益 | | | | | | | 累计 ...

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry, expecting the industry index to outperform the market index by over 10% in the next six months [1][40]. Core Insights - The SW pharmaceutical and biotechnology industry outperformed the CSI 300 index, rising by 7.84% from July 11 to July 24, 2025, exceeding the CSI 300's performance by approximately 4.13 percentage points [4][14]. - Most sub-sectors within the industry recorded positive returns during the same period, with the medical research outsourcing and raw materials sectors leading with increases of 14.23% and 9.30%, respectively [4][15]. - Approximately 91% of stocks in the industry achieved positive returns, with notable performers including Borui Pharmaceutical, which saw a weekly increase of 78.98% [16]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry outperformed the CSI 300 index, with a rise of 7.84% from July 11 to July 24, 2025, surpassing the CSI 300 by about 4.13 percentage points [14]. - Most sub-sectors recorded positive returns, particularly medical research outsourcing and raw materials, which increased by 14.23% and 9.30%, respectively [15]. - About 91% of stocks in the industry had positive returns, with Borui Pharmaceutical leading at 78.98% [16]. 2. Industry News - The report highlights the ongoing progress of the 11th batch of national drug procurement, with significant updates provided during a government open day event on July 22, 2025 [4][28]. - The announcement of the 11th batch of national drug procurement included a notification for drug information submission, which was highly anticipated [4][28]. 3. Company Announcements - Yekang Pharmaceutical announced that its subsidiary received FDA approval for clinical trials of YKYY029 injection for hypertension treatment [29]. 4. Industry Outlook - The report maintains an "Overweight" rating for the industry, citing a continuous rise in the pharmaceutical and biotechnology sector driven by positive sentiment towards innovative drugs and improved financing data [30]. - The report suggests focusing on investment opportunities within the innovative drug supply chain and highlights several companies across various segments, including medical devices, pharmaceutical commerce, and innovative drugs [30][32].

Core Viewpoint - The epidemic of Chikungunya fever in Guangdong Province remains at a high plateau, indicating a severe situation that requires attention [1]. Summary by Sections Epidemic Situation - As of July 22, 2025, Shunde District in Foshan City reported a total of 2,934 confirmed cases of Chikungunya fever, with a significant increase of 463 cases in just one day [4][5]. - The first report of the epidemic in Shunde was on July 15, 2025, with 478 confirmed cases, showing an increase of over 2,000 cases in just over a week [4]. - The World Health Organization (WHO) reported that 119 countries and regions have identified Chikungunya virus transmission, with approximately 5.5 million people at risk globally, potentially leading to widespread outbreaks [4][5]. Companies Involved in Prevention and Detection - **Runben Co., Ltd. (润本股份)**: A leading domestic company in mosquito repellent products, with a revenue of 440 million yuan in 2024, showing a year-on-year growth of 35.4% and a gross margin of 54.2% [7]. - **Rainbow Group (彩虹集团)**: A well-known pest control company in China, offering a full range of mosquito repellent products that play a crucial role in controlling Chikungunya fever [8]. - **Shanghai Jahwa (上海家化)**: The "Liushen" brand is the top brand in China for mosquito repellent flower water, holding significant brand influence in mosquito prevention and personal care [9]. - **Longyun Group (朗云集团)**: A Hong Kong-listed company that has maintained the number one market share in pest control products for ten consecutive years, with notable products performing well during the epidemic [10]. - **Kangzhi Pharmaceutical (康芝药业)**: Offers a full range of baby and child health protection products, including disinfectants and mosquito repellents, demonstrating expertise in child health protection [11]. - **Shuoshi Gene (硕世纪录物)**: Utilizes gene sequencing technology for Chikungunya fever testing, providing precise diagnostic support for epidemic prevention [12]. - **Da'an Gene (达安基因)**: Provides nucleic acid testing kits for Chikungunya virus, leveraging extensive experience in molecular diagnostics [13]. - **Huiyu Medical (会域医学)**: A leading medical testing institution in China, employing advanced technology for accurate diagnosis of Chikungunya fever [14]. - **Wansheng Biology (万学生物)**: Offers rapid testing solutions for Chikungunya virus, focusing on point-of-care testing [16]. - **Nuo Weisha (诺唯莎)**: Combines molecular design with various heat-start technologies to enhance detection efficiency for mosquito-borne viruses [17].

Group 1 - The outbreak of Chikungunya fever in Shunde District, Foshan, has reported a total of 2,934 confirmed cases as of July 22, 2025, with a significant increase of 463 cases in one day [1] - The World Health Organization (WHO) has indicated that 119 countries and regions have reported Chikungunya virus transmission, affecting approximately 5.5 million people at risk, potentially leading to widespread outbreaks [1][2] - The spread of Chikungunya fever is primarily through mosquito bites, with no direct human-to-human transmission, making it crucial to implement effective mosquito control measures to prevent further outbreaks [2] Group 2 - Companies in the relevant sectors are expected to gain market attention due to the ongoing outbreak [2] - Novogene's official WeChat account highlighted the challenges in detecting mosquito-borne viruses early due to low viral loads and complex samples, which affects testing efficiency [2] - Kangzhi Pharmaceutical has a subsidiary, Zhongshan Aihu, that offers a full range of baby and child care products, including disinfectants and mosquito repellent products [3]

Core Viewpoint - The company, Nanjing Novogene Bioinformatics Technology Co., Ltd. (诺唯赞), is planning to repurchase shares worth between 5 million to 10 million RMB as part of its employee stock ownership plan or equity incentive program, with a maximum repurchase price set at 30 RMB per share [1][2]. Group 1: Share Price and Market Capitalization - As of July 4, 2025, the share price of Novogene is 22.75 RMB, reflecting a 3.98% increase from the previous week [1]. - The highest intraday price recorded on July 3, 2025, was 23.09 RMB, while the lowest was 21.76 RMB on June 30, 2025 [1]. - The current total market capitalization of Novogene is 9.048 billion RMB, ranking 29th out of 50 in the biopharmaceutical sector and 1798th out of 5149 in the A-share market [1]. Group 2: Share Repurchase Plan - The share repurchase plan was approved during the 17th meeting of the second board of directors on June 19, 2025, allowing for the repurchase of shares using self-owned funds [2]. - The repurchase period is set from June 19, 2025, to June 18, 2026, with no shares repurchased as of June 30, 2025 [3]. - The company will make repurchase decisions based on market conditions and will fulfill its information disclosure obligations regarding the progress of the share repurchase [3].

Group 1 - The company approved a share repurchase plan on June 19, 2025, with a budget between RMB 5 million and RMB 10 million, aiming to buy back its A-shares at a price not exceeding RMB 30 per share within 12 months [1][3]. - As of June 30, 2025, the company has not yet implemented the share repurchase [2]. - The company will adhere to relevant regulations and will make repurchase decisions based on market conditions, ensuring timely disclosure of progress to investors [3].

重要内容提示： | 回购方案首次披露日 | 2025/6/20 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2025 年 6 月 | 6 | 月 | 19 | 日~2026 | 年 | 18 日 | | 预计回购金额 | 500万元~1,000万元 | | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | | | □用于转换公司可转债 | | | | | | | | | □为维护公司价值及股东权益 | | | | | | | | 累计已回购股数 | | 0股 | | | | | | | 累计已回购股数占总股本比例 | | 0% | | | | | | | 累计已回购金额 | 0万元 | | | | | | | | 实际回购价格区间 | 0元/股~0元/股 | | | | | | | 一、回购股份的基本情况 证券代码：688105 证券简称：诺唯赞 公告编号：2025-030 南京诺唯赞生物科技股份有限公司 关于以集中竞价交易方式回购公司股份 ...